# US 2024/0189226 A1 · Pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver containing polygalin c as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189226 A1
- Document ID: US20240189226A1
- Status: Published application
- Kind: A1
- Application number: 18/287,015
- Filed: 2022-04-08
- Published: 2024-06-13
- Earliest claimed: 2021-04-16
- Assignees: University-Industry Cooperation Group of Kyung Hee University
- Applicants: University-Industry Cooperation Group of Kyung Hee University
- Inventors: Hyeung Jin JANG
- Web page: https://patentgrep.com/patent/US20240189226A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 36/69: Polygalaceae (Milkwort family)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for preventing or treating obesity, wherein the pharmaceutical composition contains Polygalin C as an active ingredient. The Polygalin C not only reduces the accumulation of lipids by inhibiting the differentiation of preadipocytes into adipocytes, but also inhibits adipose tissue generation factors and adipogenic factors and modulates AMPK/ACC and MAPK/Akt signaling pathways to inhibit the differentiation of adipocytes, and thus can treat obesity more effectively. In addition, the present invention inhibits adipogenic factors and inflammatory factors in a free fatty acid-induced non-alcoholic steatohepatitis (NASH) cell model, and thus can effectively treat and prevent non-alcoholic fatty liver disease (NAFLD) including hepatic steatosis and non-alcoholic steatohepatitis.

## Claims

### Claim 1

A method of reducing body fat, comprising;
administering a health functional food comprising Polygalin C as an active ingredient to a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the body fat is selected from obesity caused by a high-fat diet or body fat caused by hormonal deficiency due to menopause.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Polygalin C inhibits differentiation of preadipocytes to suppress accumulation of lipids.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Polygalin C inhibits adipose tissue generation transcription factors and adipogenic factors.

### Claim 5 (depends on 4)

The method of claim 4, wherein the adipose tissue generation transcription factor may be one or more selected from the group consisting of a peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein (C/EBP).

### Claim 6 (depends on 4)

The method of claim 4, wherein the adipogenic factor is one or more selected from the group consisting of sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FAS).

### Claim 7 (depends on 1)

The method of claim 1, wherein the Polygalin C regulates signaling pathway of one or more selected from the group consisting of AMP-activated protein kinase/acetyl-CoA (AMPK/ACC) and mitogen-activated protein kinase/protein kinase B (MAPK/Akt).

### Claim 8 (depends on 1)

The method of claim 1, wherein the Polygalin C is contained in an amount of 0.01 to 50 parts by weight with respect to a total of 100 parts by weight of the pharmaceutical composition.

### Claim 9

(canceled)

### Claim 10

A method for preventing or treating non-alcoholic fatty liver comprising:
administering a pharmaceutical composition comprising Polygalin C as an active ingredient to a subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the non-alcoholic fatty liver is selected from hepatic steatosis or non-alcoholic steatohepatitis.

### Claim 12

A method of preventing or ameliorating non-alcoholic fatty liver, comprising:
administering a health functional food comprising Polygalin C as an active ingredient to a subject.
